Syndax Pharmaceuticals announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy. Prior to joining Syndax, Sabus served as Chief Commercial Officer at Turning Point Therapeutics, before being acquired by BMS.
Published first on TheFly
